NCT07065240Phase 2Recruiting

A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

Study sponsor: Seaport Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-03Estimated
Enrollment · participants360Estimated
Source updated2026-11-10Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.